You Searched For: B-Raf+inhibitor+1

Supplier: Apollo Scientific

Description: MAPK/ERK Signalling Pathway

Catalog Number: (USBIR0495-55C)

Supplier: US Biological

Description: Anti-Raf kinase inhibitor protein Rabbit Polyclonal Antibody

UOM: 1 * 100 µl

Sale

Catalog Number: (USBIR0495-52)

Supplier: US Biological

Description: Anti-Raf Kinase Inhibitor Protein Mouse Monoclonal Antibody [clone: 6A175]

UOM: 1 * 100 µG

Sale

Catalog Number: (USBIR0495-55B)

Supplier: US Biological

Description: Anti-Raf kinase inhibitor protein Rabbit Polyclonal Antibody

UOM: 1 * 100 µl

Sale

Supplier: ENZO LIFE SCIENCES

Description: Potent B-Raf inhibitor.

Supplier: Apollo Scientific

Description: Selective inhibitor of the mitogen-activated protein kinase kinases, MEK-1 and MEK-2, with 100-fold higher potency than PD 98059, but is, at most, a weak inhibitor of PKC, Raf, ERK, JNK, MEKK, MKK-3, MKK-4/SEK, MKK-6, Abl, Cdk2 and Cdk4. U0126 is an inhibitor of AP-1 transactivation in cell-based reporter assays. J. Biol. Chem. 273: 18623-18632 (1998).

Supplier: Apollo Scientific

Description: Sorafenib is a multikinase inhibitor of Raf-1 B-Raf and VEGFR-2 with IC50 of 6 nM 22 nM and 90 nM in cell-free assays respectively.

Supplier: ENZO LIFE SCIENCES

Description: Potent and specific inhibitor of the protein kinase c-Raf (IC50=70nM). Has no significant effect on many other protein kinases tested (even at 50µM) with the exception of p38 (SAPK2a) (IC50=2µM) and SAPK2b (p38β) (IC50=2µM). Induces a paradoxical >100-fold activation of c-Raf in whole cells.

Catalog Number: (APOSBISN0240-50MG)

Supplier: Apollo Scientific

Description: MAPK/ERK Signalling Pathway

UOM: 1 * 50 mg

Sale

Supplier: ENZO LIFE SCIENCES

Description: The Screen-Well™ Kinase Inhibitor Library contains 80 known kinase inhibitors of well-defined activity. Inhibitors are supplied dissolved in DMSO at 10 mM and aliquoted into deep-well plates at either 100 or 500 ml per well. The library is an ideal tool for chemical genomics, assay development and other pharmacological applications. Includes inhibitors of these important kinases: Insulin/IGF Receptors, PI 3-Kinase, CaM Kinase II, JAK, PKA, CDK, JNK, PKC, CKI II, MAPK, RAF, EGFR, MEK, SAPK, GSK, MLCK, Src-family, IKK, PDGFR, VEGFR and many more.

Supplier: ENZO LIFE SCIENCES

Description: Potent and selective cell permeable inhibitor of cRAF1 kinase (IC50 = 9 nM) with 100-fold selectivity over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm. A useful tool for assessing the involvement of the Ras/Raf-1/ERK pathway in various signaling pathways. Displays neuroprotective effects in vivo through a MEK-ERK and Akt-independent mechanism.

Catalog Number: (553014-1)

Supplier: Merck Millipore (Calbiochem‎)

Description: The Raf Kinase Inhibitor IV, also referenced under CAS 303727-31-3, controls the biological activity of Raf Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

UOM: 1 * 1 mg

Sale

Supplier: ENZO LIFE SCIENCES

Description: The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents.

Supplier: ENZO LIFE SCIENCES

Description: The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents.

Supplier: ENZO LIFE SCIENCES

Description: The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents.

Supplier: ENZO LIFE SCIENCES

Description: The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-alpha/beta), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents.